# LifeTech Scientific Corporation
# 先健科技公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1302)**

## VOLUNTARY ANNOUNCEMENT

## Enrollment in the China Randomized Controlled Clinical Study of IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 13 December 2022, the enrollment in the China Prospective Multicenter Randomized Controlled Clinical Study (the "**Phase II**" or the "**Study**") of the self-developed IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System ("**IBS® Coronary Scaffold**" or the "**Product**") was completed and clinical enrollment in the China Prospective Multicenter Single-arm Target Study (the "**Phase III**") will be initiated.

A total of 518 subjects were enrolled in Phase II and randomly assigned in a 1:1 ratio to the test and control groups, and the objective of the Study is to evaluate the safety and effectiveness of the IBS® Coronary Scaffold in patients with coronary heart disease. The Study took nine months from the first enrollment in March 2022 to the completion of all enrollments. Up to now, the device and surgery success rates are both 100% and no device-related serious adverse events (SAE) have occurred.

As the world's first fully degraded iron-based bioresorbable coronary scaffold, the FIM for IBS® Coronary Scaffold clinical implantation began in 2018, and it has completed the three-year follow-up, and the preliminary results demonstrate good intermediate-term safety and efficacy in simple primary coronary lesions. The completion of Phase II enrollment is another milestone for the Product, and with the advancement of follow-up clinical trials, there will be more clinical evidences to further confirm the safety and effectiveness of the Product. Upon the successful launch of the Product, the IBS® Coronary Scaffold is expected to be an unprecedented treatment for patients with coronary heart disease all over the world.

By order of the Board
**LifeTech Scientific Corporation**
**XIE Yuehui**
*Executive Director, Chairman and*
*Chief Executive Officer*

Hong Kong, 13 December 2022

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.*